Glycine Recovery Randomized Trial: What the Evidence Says

Quick Answer

Glycine Recovery Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• These changes were not dose-dependent and exhibited evidence of reversibility by the end of the recovery phase, except for the MCV recovery in males in the highest dose group. [Nagy Peter (2026); evidence level 2]
• This analysis's main strength was the inclusion of a robust overall sample size from the Phase I (N = 391), Phase II (N = 709), and Phase III (N = 1835) clinical trials, as well as additional support from nonclinical evidence. [Nagy Peter (2026); evidence level 2]
• Aging is characterized by progressive physiological decline, including loss of skeletal muscle mass and function (Sarcopenia), reduced mitochondrial efficiency, and increased oxidative stress, all of which contribute to frailty and diminished quality of life in older adults. [Wang Xiaolan (2026); evidence level 3]
• By the age of 70, individuals may experience a 25%−30% reduction in muscle mass, which is strongly associated with impaired mobility, falls, and loss of independence. [Wang Xiaolan (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For glycine recovery randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Nagy Peter (2026). The Effect of Iclepertin on Hematological Parameters: An Overview of Nonclinical Studies and Clinical Trials in Healthy Volunteers and Patients with Cognitive Impairment Associated with Schizophrenia. DOI: 10.1002/jcph.70184. PMCID: PMC13127354. PMID: 42053463. License: https://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/ This is an open access.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13127354/
• Wang Xiaolan (2026). Glycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults. DOI: 10.3389/fnut.2026.1775264. PMCID: PMC13223053. PMID: 42232577. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13223053/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.